Dyspnea

• 

  Subject Areas on Research

  • 59-Year-Old Woman With Fatigue, Dyspnea, and Lower Extremity Edema. 
  • A 27-year-old woman with cough, dyspnea, and wheezing. 
  • A 40-Year-Old Woman with Progressive Shortness of Breath, Cough, and Recurrent "Pneumonia". 
  • A 63-year-old woman with a 2-month history of dyspnea. 
  • A caravanning cardiomyopathy. 
  • A change of heart. 
  • A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. 
  • A community population survey of prevalence and severity of dyspnea in adults. 
  • A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. 
  • A review of dyspnea in acute heart failure syndromes. 
  • A review of quality of care evaluation for the palliation of dyspnea. 
  • A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. 
  • ACR Appropriateness Criteria® Dyspnea-Suspected Cardiac Origin. 
  • Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Advances in the pharmacological management of breathlessness. 
  • Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (visudyne). 
  • Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. 
  • Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. 
  • Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. 
  • Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. 
  • An interesting case of positional hypoxia: the effect of multiple synergistic pathological conditions. 
  • An unexpected echocardiographic image in a patient with dyspnea. 
  • Angiographic evaluation of chronic pulmonary embolism. 
  • Aortocaval fistula complicating abdominal aortic aneurysm: case report and literature review. 
  • Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. 
  • Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. 
  • Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. 
  • Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 
  • Atrial Septostomy to Treat Stiff Left Atrium Syndrome. 
  • B-type natriuretic peptide - a biomarker for all seasons? 
  • Beneficial effects of albuterol therapy driven by heliox versus by oxygen in severe asthma exacerbation. 
  • Bilateral nodular pulmonary infiltrates in an immunocompromised host. 
  • Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness--An Exploratory Study. 
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. 
  • Breathlessness in an age of noncommunicable diseases. 
  • Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. 
  • Bronchial provocation tests before and after cessation of smoking. 
  • Building the palliative care evidence base: Lessons from a randomized controlled trial of oxygen vs room air for refractory dyspnea. 
  • Byssinosis and chronic bronchitis among cotton textile workers. 
  • CT metrics of airway disease and emphysema in severe COPD. 
  • Can we predict which patients with refractory dyspnea will respond to opioids? 
  • Cardiac angiosarcoma presenting as progressive dyspnea on exertion. 
  • Cases from the Osler Medical Service at Johns Hopkins University. 
  • Cases from the Osler Medical Service at Johns Hopkins University. Diffuse colonic angiodysplasia with chronic iron deficiency anemia. 
  • Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. 
  • Characteristics of lung cancer in elderly patients. 
  • Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. 
  • Chronic refractory dyspnoea--evidence based management. 
  • Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. 
  • Clinical problem-solving. A hole in the argument. 
  • Clinical problem-solving. A key miscommunication--an 81-year-old woman presented to the emergency department with increasing abdominal distention, nausea, and vomiting. 
  • Clinical problem-solving. Needle in a haystack. 
  • Clinical problem-solving. Undercover and overlooked. 
  • Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. 
  • Clinically important differences in the intensity of chronic refractory breathlessness. 
  • Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. 
  • Combined use of amino terminal-pro-brain natriuretic peptide levels and QRS duration to predict left ventricular systolic dysfunction in patients with dyspnea. 
  • Common approaches to dyspnoea management in advanced life-limiting illness. 
  • Coronary arteriovenous fistulae: the complexity of coronary artery-to-coronary sinus connections. 
  • Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. 
  • Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients? 
  • Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. 
  • Critical arrhythmia associated with pulmonary artery catheterization in a parturient with severe pulmonary hypertension. 
  • Decongestion in acute heart failure. 
  • Delayed postmyectomy ventricular septal defect. 
  • Diagnosis of pheochromocytoma on physical examination. 
  • Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. 
  • Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. 
  • Distant wheezes. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. 
  • Does This Child Have Pneumonia?: The Rational Clinical Examination Systematic Review. 
  • Does palliative home oxygen improve dyspnoea? A consecutive cohort study. 
  • Does this patient have pulmonary embolism? 
  • Dyspnea and hypoxia in a 64-year-old male traveler. 
  • Dyspnea and pain frequently co-occur among Medicare managed care recipients. 
  • Dyspnea review for the palliative care professional: assessment, burdens, and etiologies. 
  • Dyspnea review for the palliative care professional: treatment goals and therapeutic options. 
  • Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. 
  • Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 
  • Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. 
  • Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 
  • Effect of nesiritide in patients with acute decompensated heart failure. 
  • Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. 
  • Effects of low-dose morphine on perceived sleep quality in patients with refractory breathlessness: A hypothesis generating study. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 
  • Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. 
  • Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. 
  • Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. 
  • Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. 
  • Evaluation of a provocative dyspnea severity score in acute heart failure. 
  • Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference. 
  • Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. 
  • Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? 
  • Hemodynamic findings in severe tricuspid regurgitation. 
  • Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment. 
  • Ideas whose times have come. 
  • Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. 
  • Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. 
  • Improving the management of dyspnea in the community using rapid learning approaches. 
  • Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. 
  • Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 
  • Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients. 
  • Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Lung volume reduction surgery for the management of refractory dyspnea in chronic obstructive pulmonary disease. 
  • Management of dyspnea in advanced lung cancer: recent data and emerging concepts. 
  • Management of dyspnea in patients with chronic obstructive pulmonary disease. 
  • Management of dyspnea within a rapid learning healthcare model. 
  • Management of terminal cancer in elderly patients. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. 
  • Measuring improvement in dyspnoea: should absolute or relative values be used? 
  • Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. 
  • Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. 
  • Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. 
  • Morphine for management of refractory dyspnoea: opiates should be used with caution. 
  • N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. 
  • NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. 
  • NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. 
  • National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. 
  • Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. 
  • Natriuretic peptides in the diagnosis and management of heart failure. 
  • Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 
  • Nesiritide in acute decompensated heart failure. 
  • Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. 
  • Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. 
  • Opioids for chronic refractory breathlessness: patient predictors of beneficial response. 
  • Opioids for chronic refractory breathlessness: right patient, right route? 
  • Optimal management of malignant pleural effusions (results of CALGB 30102). 
  • Outcomes after esophagectomy: a ten-year prospective cohort. 
  • Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. 
  • Oxygen for relief of dyspnea: what is the evidence? 
  • Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. 
  • Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. 
  • Oxygen use--patients define symptomatic benefit discerningly. 
  • Ozone-induced respiratory symptoms: exposure-response models and association with lung function. 
  • Palliative management of refractory dyspnea in COPD. 
  • Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era. 
  • Peripartum cardiomyopathy presenting as an acute myocardial infarction. 
  • Pharmacological management of dyspnoea. 
  • Phenotype of Spirometric Impairment in an Aging Population. 
  • Platypnea-Orthodeoxia Syndrome: To Shunt or Not to Shunt, That is the Question. 
  • Platypnea-orthodeoxia and progressive autonomic failure. 
  • Positional dyspnea and tracheal compression as indications for goiter resection. 
  • Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. 
  • Potential opioid-sparing effect of regular benzodiazepines in dyspnea: longer duration of studies needed. 
  • Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity. 
  • Predictors of chronic breathlessness: a large population study. 
  • Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 
  • Preprocessing cotton to prevent byssinosis. 
  • Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. 
  • Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). 
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. 
  • Prospectively collected characteristics of adult patients, their consultations and outcomes as they report breathlessness when presenting to general practice in Australia. 
  • Pseudo-tumor of the lung, a rare clinical presentation of dirofilariasis. 
  • Pulmonary embolism. 
  • Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. 
  • Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME). 
  • Ranolazine-related dyspnea on exertion. 
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. 
  • Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). 
  • Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department. 
  • Reader questions benefit of nebulized opioids. 
  • Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. 
  • Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. 
  • Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. 
  • Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects. 
  • Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
  • Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. 
  • Researching breathlessness in palliative care: consensus statement of the National Cancer Research Institute Palliative Care Breathlessness Subgroup. 
  • ST2: a novel biomarker for heart failure. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 
  • Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. 
  • Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 
  • Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. 
  • Short-term effects of formaldehyde on peak expiratory flow and irritant symptoms. 
  • Shortness of breath and edema after heart surgery. 
  • Shortness of breath as a predictor of depressive symptoms in a community sample of older adults. 
  • Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. 
  • Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. 
  • Study protocol: a phase III randomised, double-blind, parallel arm, stratified, block randomised, placebo-controlled trial investigating the clinical effect and cost-effectiveness of sertraline for the palliative relief of breathlessness in people with chronic breathlessness. 
  • Sudden onset of headache and recent breathlessness. 
  • Symptom Burden and Performance Status among Community-Dwelling Patients with Serious Illness. 
  • Symptom Burden of Chronic Lung Disease Compared with Lung Cancer at Time of Referral for Palliative Care Consultation. 
  • Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. 
  • The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The Prospective Evaluation of the Net Effect of Red Blood Cell Transfusions in Routine Provision of Palliative Care. 
  • The Rational Clinical Examination. Does this patient have abnormal central venous pressure? 
  • The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. 
  • The active identification and management of chronic refractory breathlessness is a human right. 
  • The clinical and social dimensions of prescribing palliative home oxygen for refractory dyspnea. 
  • The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 
  • The evidence base for oxygen for chronic refractory breathlessness: issues, gaps, and a future work plan. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. 
  • The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea. 
  • The management of chronic breathlessness in patients with advanced and terminal illness. 
  • The need to research refractory breathlessness. 
  • The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. 
  • The science of breathlessness: '… as we come onto the home straight, Science is catching Clinical Practice. Just two lengths between them'. 
  • The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. 
  • Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. 
  • Therapeutic nihilism: the next hurdle in improving the treatment of breathlessness. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 
  • To what causes do people attribute their chronic breathlessness? A population survey. 
  • Total dyspnoea. 
  • Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. 
  • Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). 
  • Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. 
  • Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. 
  • Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. 
  • WITHDRAWN: Oxygen therapy for dyspnoea in adults. 
• 

  Keywords of People

  • Abbruzzese, James, D. C. I. Professor of Medical Oncology, Medicine, Medical Oncology
  • ElMallah, Mai, Associate Professor of Pediatrics, Pediatrics, Pulmonary and Sleep Medicine
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic